

July 19, 2019

Listing Department  
**BSE LIMITED**  
P J Towers, Dalal Street, Fort,  
Mumbai-400 001

**Code: 532 321**

Listing Department  
**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E),  
Mumbai-400 051

**Code: CADILAHC**

**Re.: Press Release**

Dear Sir / Madam,

Please find enclosed a copy of press release dated July 19, 2019 titled "Zydus' Neshar Pharmaceuticals receives final approval from the USFDA for Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate ER Capsules".


The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,  
For, **CADILA HEALTHCARE LIMITED**

  
**DHAVAL N. SONI**  
**COMPANY SECRETARY**



Encl.: As above

## **Zydus' Neshor Pharmaceuticals receives final approval from the USFDA for Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate ER Capsules**

*Ahmedabad, 19 July, 2019*

Zydus' Neshor Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received the final approval from the USFDA to market Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate, Extended-Release Capsules (US RLD – ADDERALL XR<sup>®</sup>), 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg.

The drug is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) which is a brain disorder characterized by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. It will be manufactured at Neshor Pharmaceuticals' manufacturing facility located at St. Louis, MO, USA.

The group now has 269 approvals and has so far filed over 360 ANDAs since the commencement of the filing process in FY 2003-04.

### **About Zydus Cadila**

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

\*\*\*